| Excerpt | Reference |
|---|
| "Overactive bladder is commonly treated with oral anticholinergic drugs such as oxybutynin chloride." | ( Davila, GW; Dmochowski, RR; Starkman, JS, 2006) |
| "Overactive bladder is a common and disabling problem." | ( Patel, HR; Shaw, GL, 2007) |
| "The overactive bladder is a common and distressing condition that has a significant impact on the quality of life of many people worldwide." | ( McKay, N; Sellers, DJ, 2007) |
| "Overactive bladder is a dreadful syndrome that affects a considerable number of patients." | ( Davila, GW, 2006) |
| "Overactive bladder is a complex and widely prevalent condition, but little is known about its physiopathology." | ( Abdalla, FM; Antunes, E; Báu, FR; Bricola, AA; De Nucci, G; Freitas, LL; Mónica, FZ; Muscará, MN; Porto, CS; Teixeira, SA; Zanesco, A, 2008) |
| "Overactive bladder is a problem that many women experience and suffer with in silence for years." | ( Spilde, NL, 2008) |
| "Overactive bladder is a common condition that has a negative impact on the quality of life of the affected individuals." | ( Arruda, RM; Castro, R; Girão, MJ; Sartori, M, 2009) |
| "Overactive bladder is highly prevalent among patients with Parkinson disease." | ( Chancellor, MB; de Groat, WC; Kitta, T; Kuno, S; Nonomura, K; Yoshimura, N, 2012) |
| "Overactive bladder is a common condition and is significantly known to affect quality of life in both men and women." | ( Hollingworth, T; Kaler, M; Sharma, S; Wuntakal, R, 2012) |
| "Overactive bladder is a common disorder that affects approximately 34 million adults in the United States." | ( Harnett, MD; MacLean, L; Sandage, BW; Schwiderski, U; Shipley, J, 2013) |
| "Overactive bladder is a prevalent condition worldwide that is associated with a considerable burden, both on the patient and on society." | ( Angulo, JC; Kvasz, M; Linden, K; Rejas, J; Snedecor, SJ; Valpas, A, 2014) |
| "Overactive bladder is defined by ICS as urgency frequency and nocturia, with or without urgency urinary incontinence in the absence of urinary tract infection, or other obvious causative pathology Lower urinary tract symptoms (LUTS) are highly prevalent, especially in aging populations." | ( Kulik-Rechberger, B; Miotła, P; Rechberger, T; Wróbel, A, 2014) |
| "Overactive bladder is a difficult to treat condition affecting a large proportion of adults resulting in considerable economic impact to society." | ( Mayr, CA; Shepherd, JP, 2014) |
| "Overactive bladder is a syndrome of urinary frequency and urgency, with or without urge incontinence, in the absence of local pathological factors." | ( Mutambirwa, S; Sharma, JB; Sweeney, P; Van An, N; Vanamail, P, 2016) |
| "Overactive bladder is a common symptom complex with health related quality of life impacts on the individual as well as utilizing health resources." | ( Cardozo, L; Izett, M; Robinson, D; Thiagamoorthy, G; Zacche, M, 2017) |
| "Overactive bladder is a composite of lower urinary tract storage symptoms." | ( Colomer, MEB; Dolcet, MJL; Fernández-Liz, E; Martínez, AA; Rebull, JO; Tristante, PV, 2018) |
| "Overactive bladder is a complex of symptoms including a compelling desire to pass urine that leads to increased frequency, which may lead to a degree of incontinence if you do not reach the toilet in time and may wake you from sleep." | ( Cardozo, L; Chapple, CR; Choudhury, N; Cruz, F; Heesakkers, J; Herschorn, S; Siddiqui, E; Staskin, D; Stoelzel, M, 2020) |
| "Overactive bladder is a troublesome disease that affects 15% of the population in developed countries." | ( Poleszak, E; Serefko, A; Szopa, A; Wróbel, A, 2020) |
| "Overactive bladder is defined as "urgency, with or without urge incontinence, usually with frequency and nocturia"." | ( Chen, W; Li, H; Li, N; Liu, Z; Lu, Y; Tian, F; Wang, X; Wen, Q, 2020) |
| "Idiopathic Overactive Bladder is the most common cause of urinary incontinence in children." | ( Brown, M; Goyal, A; Lewis, M; Melling, C; Sutton, L; Webb, NJA; Williamson, PR, 2021) |
| "Overactive bladder is highly prevalent in men." | ( Brucker, B; Bschleipfer, T; Cornu, JN; De Nunzio, C; Drake, MJ; Fusco, F; Gravas, S; Madersbacher, S; Oelke, M; Peyronnet, B; Tutolo, M; van Koeveringe, G, 2021) |
| "Overactive bladder is a condition that quite a lot reduces the quality of life of our patients." | ( Habeš, Dominik; Kestřánek, Jan; Leško, Daniel; Špaček, Jiří; Štěpán, Martin, 2021) |
| "Overactive bladder is a condition that affects both men and women, and significantly affects patients' quality of life." | ( Shimizu, S, 2023) |
| Excerpt | Reference |
|---|
| "Anticholinergics act in the treatment of overactive bladder by blocking muscarinic receptors of which five subtypes exist." | ( Barendrecht, MM; Michel, MC; Oelke, M, 2006) |
| "The primary pharmacological therapy for overactive bladder syndrome is muscarinic receptor antagonists." | ( Madersbacher, H; Rovner, E, 2006) |
| "Men with overactive bladder and other lower urinary tract symptoms may not respond to monotherapy with antimuscarinic agents or alpha-receptor antagonists." | ( Bavendam, T; Carlsson, M; Guan, Z; Kaplan, SA; Roehrborn, CG; Rovner, ES, 2006) |
| "Urgency UI is a symptom of overactive bladder (OAB) and antimuscarinic agents are a first-line treatment for OAB symptoms; several studies have used dryness rate as an efficacy endpoint, calculated as the percentage of patients who record no UI episodes in a diary period." | ( Guan, Z; Khullar, V; Wang, JT; Wein, AJ, 2007) |
| "It is a rare complication of therapy for overactive bladder and resolved when dosage was reduced to 1 mg, although overactive bladder symptoms were still controlled." | ( Bolis, P; Cardozo, L; Salvatore, S; Serati, M; Uccella, S, 2007) |
| "The primary goal of overactive bladder (OAB) treatment is to reduce symptoms and improve health-related quality of life (HRQoL)." | ( Capo', JP; Fakhoury, A; Forero-Schwanhaeuser, S; Laramée, C; Lucente, V, 2008) |
| "At the therapeutic dose used to treat overactive bladder, tolterodine did not significantly affect gastrointestinal or colonic transit and had minor effects on bowel habits in healthy subjects." | ( Andrews, CN; Bharucha, AE; Guan, Z; Seide, B; Zinsmeister, AR, 2008) |
| "Men and women who had overactive bladder symptoms were randomized equally to double-blind treatment with 0." | ( Homma, Y; Yamaguchi, O; Yamaguchi, T, 2008) |
| "We evaluated overactive bladder (OAB) symptoms and sexual and emotional health in sexually active women with OAB/urgency urinary incontinence (UUI) treated with tolterodine extended release (ER)." | ( Bachmann, G; Bavendam, T; Guan, Z; Jumadilova, Z; Morrow, JD; Rogers, R; Sun, F, 2008) |
| "The standard therapy for overactive bladder includes behavioural therapy and sometimes medication." | ( Al, MJ; Hakkaart, L; Phillips, R; Verboom, P, 2009) |
| "Men and women who had overactive bladder symptoms were enrolled for open-label treatment with 0." | ( Homma, Y; Yamaguchi, O, 2008) |
| "Patient perception of overactive bladder (OAB) treatment outcomes can be a useful indicator of benefit and may help drive persistence on treatment, which is known to be poor in OAB." | ( Ebinger, U; Egermark, M; Kobashi, KC; Koochaki, P; Quebe-Fehling, E; Viegas, A; Zinner, N, 2008) |
| "Voiding diaries and an overactive bladder questionnaire were completed at baseline and at the end of therapy to compare 24-hour voiding frequency, urinary urge incontinence episodes, voids causing waking, volume voided, urgency episodes and quality of life indices." | ( Feagins, BA; Jarnagin, BK; Leong, FC; Macdiarmid, SA; Peters, KM; Rosenblatt, PL; Rovner, ES; Shobeiri, SA; Siegel, SW; Tate, SB; Wooldridge, LS, 2009) |
| "In children with refractory overactive bladder double anticholinergic therapy is an efficient and serious alternative to surgery." | ( Bolduc, S; Hamel, M; Lamontagne, P; Lebel, S; Moore, K, 2009) |
| "Oral antimuscarinic treatment for overactive bladder might significantly alter HRV, which is an important predictor for cardiac and all-cause mortality." | ( Mehnert, U; Sauermann, P; Schiffers, M; Schurch, B, 2010) |
| "Severity of overactive bladder symptoms decreased significantly in both treatment groups." | ( Akyol, I; Alanbay, I; Atay, V; Ceyhan, ST; Muhcu, M; Mutlu Ercan, C; Sancaktar, M, 2010) |
| "Changes in Overactive Bladder Symptom Score (OABSS), International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), and King's Health Questionnaire (KHQ) as well as changes in number of voids, amount of each void, and number of leaks in 24h according to the 3-day voiding diary were also evaluated before treatment and at weeks 4 and 12 after treatment." | ( Honda, M; Sakakibara, R; Uchiyama, T; Watanabe, M; Yamanishi, T; Yoshida, K, 2010) |
| "A total of 204 children with idiopathic overactive bladder were randomly divided into three groups (n=68 each): placebo, tolterodine-treated and oxybutynin-treated." | ( Chen, CJ; Deng, YJ; Ge, Z; Guo, YF; Lu, RG; Ma, G; Wang, LX; Zhu, HB, 2011) |
| "Research has focused on treatment of overactive bladder (OAB) symptoms in women with the goal of cure." | ( Anger, JT; Le, TX; Lee, U; Litwin, MS; Maliski, SL; Nissim, HA; Raz, S; Rodriguez, LV; Sarkisian, C; Smith, AL, 2011) |
| "The treatment of patients with overactive bladder (OAB) refractory to conventional treatment is gaining clinical significance." | ( Hamann, M; Jünemann, KP; Knüpfer, S; Melchior, D; Naumann, CM, 2011) |
| "To measure reliability, women with overactive bladder (OAB) completed the USIQ on two separate occasions, prior to treatment for OAB." | ( Brubaker, L; Fitzgerald, MP; Fordham, J; Kenton, K; Lowenstein, L; Mueller, ER; Rickey, L; Tulke, M, 2012) |
| "The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial was a two-site randomized, controlled, equivalence trial with 4-week alpha-blocker run-in." | ( Burgio, KL; Colli, J; Goode, PS; Hammontree, L; Johnson, TM; Markland, AD; Ouslander, JG; Redden, DT; Vaughan, CP, 2011) |
| "Antimuscarinics are the mainstay of overactive bladder (OAB) pharmacotherapy although other agents, such as α-adrenergic receptor antagonists, might also be effective." | ( Cho, KJ; Kim, JC, 2012) |
| "To evaluate the therapeutic effect of overactive bladder after transurethral resection of prostate (TURP) preventively treated with electroacupuncture and Tolterodine." | ( Lin, Q; Lin, X; Shen, YZ, 2012) |
| "Many patients with overactive bladder discontinue pharmacotherapy due to suboptimal efficacy or side effects." | ( Auerbach, S; Calhoun, A; Herschorn, S; Lee, M; Martin, N; Nitti, VW, 2013) |
| "Thus, treatment of most patients with overactive bladder with once-daily trospium chloride 60 mg XR should not require consideration of key intrinsic demographic parameters." | ( Harnett, MD; MacLean, L; Sandage, BW; Schwiderski, U; Shipley, J, 2013) |
| "Women with overactive bladder and urodynamic diagnosis of detrusor overactivity who were refractory to anticholinergics, and had histological evidence of urothelial inflammation were treated with a 6-week course of rotating antibiotics." | ( Cartwright, R; Derpapas, A; Fernando, R; Gallo, P; Khullar, V; Vijaya, G, 2013) |
| "Women with refractory overactive bladder and elevated NGF may benefit from antibiotic treatment." | ( Cartwright, R; Derpapas, A; Fernando, R; Gallo, P; Khullar, V; Vijaya, G, 2013) |
| "To determine the course of overactive bladder (OAB) symptoms after 4 weeks of no treatment following a 12-week study of the efficacy and safety of flexible-dose fesoterodine in patients with OAB who were enrolled in the UK healthcare system." | ( Arumi, D; Cardozo, L; Darekar, A; Ebel Bitoun, C; Hall, T; Kelleher, CJ; Khullar, V; Ryan, J; Wagg, A, 2013) |
| "We assessed the overactive bladder symptom score (OABSS), thirst, and constipation at baseline, as well as at 3 and 6 months from the start of drug administration." | ( Nakanishi, S, 2013) |
| "A total of 110 patients with de novo overactive bladder after obturator tension-free vaginal tape placement completed solifenacin treatment and were included in group 1." | ( Braga, A; Ghezzi, F; Salvatore, S; Serati, M; Siesto, G; Sorice, P, 2014) |
| "This study was conducted using the overactive bladder symptom score (OABSS) to evaluate the efficacy of solifenacin succinate for the treatment of OAB." | ( An, R; Guan, Z; Guo, H; He, D; Huang, J; Huang, Y; Kong, C; Li, H; Liao, L; Liu, M; Shen, Z; Song, B; Song, X; Sun, Y; Wang, D; Wang, J; Wang, X; Wen, J; Xiao, J; Yang, Y; Ye, Z; Zeng, P; Zhang, X; Zhao, X; Zheng, S, 2014) |
| "In patients with LUTS and overactive bladder, combined therapy with alfuzosin 10 mg plus propiverine 20 mg was significantly more effective than alfuzosin monotherapy and propiverine 10 mg combined therapy in terms of improving OABSS while not significantly affecting Qmax or PVR." | ( Cho, HJ; Cho, JM; Kang, JY; Moon, HS; Seo, DY; Shin, SC; Sung, LH; Yoo, TK; Yu, JH, 2014) |
| "Two study populations, one of women with overactive bladder (OAB) and urgency UI (UUI) treated with tolterodine in a placebo-controlled trial (cohort I), and one of women treated surgically for prolapse and/or UI (cohort II) were used." | ( Mamik, MM; Morrow, JD; Qualls, CR; Rogers, RG, 2014) |
| "To improve treatment of overactive bladder (OAB), mirabegron/solifenacin in combination was compared with each drug alone and placebo." | ( Abrams, P; Kay, R; Kelleher, C; Martina, R; Newgreen, D; Paireddy, A; Rechberger, T; Ridder, A; Staskin, D; van Maanen, R, 2015) |
| "In an observational study, most overactive bladder patients were satisfied with fesoterodine treatment." | ( Arumi, D; Crook, TJ; Michel, MC; Schneider, T; Sun, F, 2014) |
| "The symptoms of overactive bladder (OAB) can be treated with oral medications using a variety of antimuscarinic medications and, more recently, mirabegron, a beta-3 agonist." | ( Peters, GL; Vouri, SM, 2014) |
| "The two groups of female patients with overactive bladder were given treatment with weekly acupuncture (n = 118), oral tolterodine tartrate (n = 122) for 4 weeks respectively." | ( He, C; Huang, D; Tang, W; Wang, H; Yan, S; Yuan, Z, 2015) |
| "To evaluate Overactive bladder (OAB) with detrusor overactivity (DOA) following oxybutynin or tolterodine treatment in recommended doses at a four-week course." | ( Azimi Nekoo, E; Ghanbari, Z; Haghollahi, F; Hashemi, S; Jafarabadi, M; Nemati, M, 2015) |
| "To investigate the etiology of overactive bladder (OAB) symptoms during secondary treatment following initial unsuccessful therapy with α1-blockers in benign prostatic hyperplasia (BPH)/OAB patients." | ( Asai, K; Gotoh, M; Kashiwagi, Y; Kasugai, S; Kato, M; Komatsu, T; Matsukawa, Y; Narita, H; Takai, S; Yamamoto, T, 2015) |
| "The effectiveness of overactive bladder treatment with M-cholinoblocker solifenacin (Vesicare) as monotherapy and in combination with α1-andrenoblocker terazosin (Setegis) or bladdrer training in elderly patients was evaluated." | ( Kagan, OF; Kheĭfets, VKh; Sosnovskiĭ, SO, 2015) |
| "To assess the costs of treating overactive bladder (OAB) with fesoterodine compared to no OAB pharmacotherapy among vulnerable elderly from the US payer perspective." | ( Luo, X; Qin, L; Snedecor, SJ; Zou, KH, 2016) |
| "In women with overactive bladder receiving fesoterodine dry mouth may prevent restriction of fluid intake but does not diminish treatment efficacy." | ( Arya, LA; Harvie, HS; Lewis, R; Miller, JM; Smith, AL; Weissbart, SJ, 2016) |
| "In this 12-wk study, overactive bladder patients who remained incontinent despite initial solifenacin 5mg treatment received additional treatment with mirabegron 50mg." | ( Athanasiou, S; Cambronero, J; Chapple, C; Drake, MJ; Esen, AA; Herholdt, C; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Saleem, T; Siddiqui, E; Stölzel, M, 2016) |
| "We investigated improvements in overactive bladder and patient reported outcomes in patients with overactive bladder and refractory incontinence treated with mirabegron 50 mg plus solifenacin 5 mg vs solifenacin 5 or 10 mg." | ( Al-Shukri, S; Barkin, J; Drake, MJ; Fianu-Jonasson, A; Grise, P; Hakimi, Z; Hemsted, C; Herschorn, S; Huang, M; MacDiarmid, S; Nazir, J; Saleem, T; Siddiqui, E; Stölzel, M, 2016) |
| "To determine if treatment of overactive bladder (OAB) can improve self-reported limitations in physical activity in women." | ( Andy, UU; Arya, LA; Chu, CM; Harvie, HS; Smith, AL, 2016) |
| "After solifenacin treatment, the overactive bladder symptom score and average voided volume were significantly improved and maintained for 3 years." | ( Masumori, N; Tanaka, Y; Tanuma, Y, 2016) |
| "Oral pharmacological treatment for overactive bladder (OAB) consists of antimuscarinics and the beta-3 adrenergic agonist mirabegron." | ( Campbell, NL; Klein, RW; Klein, TM; Ng, DB; Perk, S; Perkins, A; Posta, LM; Wielage, RC; Yuran, T, 2016) |
| "Participants had overactive bladder, a history of/coexisting cardiovascular disease and a 12-lead electrocardiogram carried out ≤7 days before initiating 4 weeks of mirabegron treatment." | ( Kato, D; Katoh, T; Kuroishi, K; Kuwamoto, K, 2016) |
| "The Indevus Urgency Severity Scale, overactive bladder symptom score (Homma et al, 2006), and a 3-day micturition diary with frequency, incontinence, and urgency episodes were recorded and compared before the treatment, every 2 weeks following the treatment, and 3 months after the treatment." | ( Chen, B; Chen, H; Dai, S; Liu, C; Lv, J; Wang, F; Yu, Z; Zhang, Y, 2017) |
| "To describe the profile of the overactive bladder (OAB) patient on treatment with flexible-dose antimuscarinic treatment in daily clinical practice." | ( Arumi, D; García-Mediero, JM; Lizarraga, I; Sánchez-Ballester, F; Sobrón-Bustamante, M, 2016) |
| "The mainstay of overactive bladder treatment is the use of anticholinergic medication with its common side effects well known." | ( Araklitis, G; Cardozo, L, 2017) |
| "Symptoms of overactive bladder, such as the urgent need to visit the toilet, incontinence, and frequent urination, were improved with all treatments regardless of the patient's age, but combination treatment demonstrated the greatest benefit, and was well tolerated." | ( Choudhury, N; Drake, MJ; Gibson, W; Huang, M; MacDiarmid, S; Siddiqui, E; Stölzel, M, 2017) |
| "In the overactive bladder symptom score, night-time frequency, urgency and the total score improved after oral prosultiamine treatment (P = 0." | ( Matsuo, T; Miyata, Y; Nakamura, T; Sakai, H; Satoh, K, 2018) |
| "Clinical effects, evaluated using the Overactive Bladder Symptom Score (OABSS), Urinary Sensation Scale (USS), International Prostate Symptom Score (IPSS), and Patient Perception of Bladder Condition (PPBC), as well as urodynamic parameters and adverse events were assessed at baseline and 4 and 12 weeks after treatment." | ( Chen, SF; Kuo, HC, 2019) |
| "Pharmacotherapy of overactive bladder (OAB) typically involves treatment with an antimuscarinic or mirabegron, a β3-adrenoceptor agonist, but real-world evidence on their use, including treatment access, persistence, and switching, is limited." | ( Carlson, KV; Deal, AS; Gemmen, E; Gooch, KL; Kristy, RM; Nair, KV; Oakkar, EE; Park, J; Rovner, ES; Schermer, CR, 2018) |
| "Patients with overactive bladder were prospectively treated with 25 mg of mirabegron once daily." | ( Kuo, HC; Lee, YK, 2018) |
| "For managing overactive bladder (OAB), mirabegron, a β3 adrenergic receptor agonist, is typically used as second-line pharmacotherapy after antimuscarinics." | ( Gooch, KL; Johnston, KM; Khangulov, V; Rumsfeld, JS; Schermer, CR; Szabo, SM; Vonesh, E, 2018) |
| "Older patients with overactive bladder under antimuscarinic treatment are especially susceptible to cognitive impairment." | ( Arlandis-Guzman, S; Batista-Miranda, JE; Casas Nebra, J; El Khoury Moreno, R; Errando-Smet, C; Gonzalez Garcia, O; Leva Vallejo, M; Morales Solchaga, G; Müller-Arteaga, C; Zubiaur Libano, C, 2019) |
| "Antimuscarinics, commonly used to treat overactive bladder, produce modest efficacy and unwanted side effects." | ( Bennett, N; Frenkl, TL; Green, S; Mitcheson, HD; Mudd, PN; Muldowney, K; Pinto, CA; Rocha, BA; Samanta, S, 2019) |
| "Treatment of overactive bladder (OAB) with antimuscarinic agents has been shown to improve depression and/or anxiety symptoms." | ( Fukuhara, H; Kinjo, M; Okegawa, T; Tambo, M; Yamaguchi, T, 2019) |
| "In women with overactive bladder, urinary Ach and Ch levels are higher in responders to anticholinergic therapy compared with nonresponders." | ( El-Nashar, S; Hazlett, FE; Hijaz, AK; Li, X; Mahajan, ST; Mangel, JM; Mara, E; Sheyn, D, 2020) |
| "They completed self-administered Overactive Bladder questionnaire short form (OABq), Morisky Medication Adherence Scale-4 short form (MMAS), Patient Global Impression-Improvement questionnaire." | ( Balsamo, R; Costantini, E; Finazzi Agrò, E; Illiano, E; Natale, F, 2020) |
| "Treating overactive bladder syndrome in women with myofascial trigger point electroacupuncture combined with solifenacin succinate can significantly improve the OABSS and improve the life quality of the patients." | ( Li, X; Liu, Q; Shi, R; Sun, S; Tang, Y; Xiang, J; Xiang, Y; Xiong, C; Yang, S; Zhou, Y, 2020) |
| "We assessed the overactive bladder symptom score (OABSS), thirst, constipation, and residual urine at baseline, as well as at 3 and 6 months from the start of drug administration." | ( Nakanishi, S, 2020) |
| "At the beginning of the treatment, the overactive bladder-version 8 form was filled and potassium citrate 10 meq 2x2 dose was started to the patients." | ( Akkoc, A; Demir, M; Ozturk, SA; Topcuoglu, M; Uçar, M, 2020) |
| "The role of overactive bladder (OAB) treatment in women beyond antimuscarinics has been evaluated extensively." | ( Brucker, B; Bschleipfer, T; Cornu, JN; De Nunzio, C; Drake, MJ; Fusco, F; Gravas, S; Madersbacher, S; Oelke, M; Peyronnet, B; Tutolo, M; van Koeveringe, G, 2021) |
| "The primary endpoint was change in the overactive Bladder (OAB) Symptom Score from baseline to end of treatment." | ( Hiramatsu, I; Honda, S; Horie, S; Ishikawa, K; Iwata, S; Mitsuhashi, I; Miyoshi, M; Miyoshi, Y; Mizuno, T; Noto, K; Nozaki, T; Ogasa, T; Shigeta, Y; Shirai, M; Sugimura, S; Tsujimura, A; Uesaka, Y, 2021) |
| "Participants were adults diagnosed with overactive bladder (OAB) by their health care provider (HCP), who were initiating mirabegron or antimuscarinic treatment." | ( Carlson, KV; Deal, AS; Hairston, JC; Kristy, RM; Nair, KV; Rovner, ES, 2021) |
| "In older women with overactive bladder, short-term treatment with fesoterodine decreased objectively measured physical activity with no significant change in physical function." | ( Andy, UU; Arya, LA; Chu, CM; Harvie, H, 2021) |
| "These results can help patients with overactive bladder understand their own chances of treatment success with fesoterodine and can help doctors support their patients on what to expect regarding their specific symptoms and concerns." | ( Carlsson, M; Fernet, M; Herschorn, S; Oelke, M; Wagg, AS, 2022) |
| "Patients' overactive bladder symptom scores (OABSS) were collected before and after mirabegron treatment and patients were divided into effective and ineffective groups." | ( Feng, Z; Huang, P; Li, K; Qiu, Y; Sun, Q; Wang, B; Wu, P; Xie, M; Xue, J; Yu, Y; Zhao, J; Zhou, Z; Zhu, Z, 2022) |
| "Patients' overactive bladder symptom scores (OABSS) were collected before and after mirabegron treatment and patients were divided into effective and ineffective groups." | ( Feng, Z; Huang, P; Li, K; Qiu, Y; Sun, Q; Wang, B; Wu, P; Xie, M; Xue, J; Yu, Y; Zhao, J; Zhou, Z; Zhu, Z, 2022) |
| "Compared to other treatments for overactive bladder, OnabotulinumtoxinA is more cost-effective and less invasive." | ( Dasgupta, P; Khan, MS; Khan, N; Malde, S; Sahai, A, 2023) |
| "Medical treatments for overactive bladder (OAB) have proven efficacy in controlled trials." | ( Chen, S; Grotz, O; Igor, M; Jack, B; Karin, L; Ofer, Y; Shachar, A; Yariv, S, 2023) |
| "To assess the prescribing practices for overactive bladder (OAB) pharmacotherapy based on the prescription trend analysis across different specialties of India." | ( Hiren Prajapati, HP; Krunal Vishavadia, KV; Madhu Sharma, MS; Sandip Solanki, SS, 2023) |